Funding

The company will use the capital to support ongoing clinical trials of its injectable Discogenic Cell Therapy (IDCT) for lumbar degenerative disc disease.

The company raises the funds through a non-brokered private placement. The proceeds will fund initiatives like securing FDA approval for clinical trials.

The $4 million round will support additional preclinical testing for the BioPrax device to eliminate biofilm infections on prosthetic joints.

Funds will support new product development and launch, including the recently FDA-cleared APEX 3D Total Ankle Replacement.

Lapiplasty is an instrumented, reproducible approach to 3-plane bunion correction with rapid return to weight-bearing.

Impressio and MedShape were awarded a $250,000 grant for research and development of a new surgical treatment for hallux rigidus.

Proceeds will support completing the RESTORE Clinical Study and beginning commercialization activities for the CurvaFix Rodscrew.

Bioventus has an agreed option structure to acquire CartiHeal upon milestone achievements, such as FDA approval of the Agili-C implant.

The company also partnered with Ortho Consulting Group to establish and support KAHTNU Surgical sales channels outside the U.S.

The financing supports clinical launch of the aprevo system, which makes surgical plans and devices tailored to the needs of each patient.